Regulation of cellular redox signaling by matricellular proteins in vascular biology, immunology, and cancer

Antioxidants and Redox Signaling

Volumn 27, Issue 12, 2017, Pages 874-911

  Roberts, David D ^a   Kaur, Sukhbir ^a   Isenberg, Jeffrey S ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

CD47; Hydrogen sulfide; Matricellular proteins; Nitric oxide; Reactive oxygen species; Thrombospondin 1

Indexed keywords

ADAMTS1 PROTEIN; BIOLOGICAL MARKER; CD47 ANTIGEN; CELL SURFACE RECEPTOR; CYSTEINE RICH PROTEIN 61; GUANYLATE CYCLASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MATRICELLULAR PROTEIN; NITRIC OXIDE; OSTEOPONTIN; PROTEIN; SUPEROXIDE; TENASCIN; THROMBOSPONDIN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR; CD47 PROTEIN, HUMAN; CYR61 PROTEIN, HUMAN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SCLEROPROTEIN; SPZ1 PROTEIN, HUMAN;

APOPTOSIS; CARBOXY TERMINAL SEQUENCE; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; EXTRACELLULAR MATRIX; FOCAL ADHESION; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMMUNOLOGY; IN VIVO STUDY; KIDNEY CELL; LUNG DISEASE; MALIGNANT NEOPLASM; MARFAN SYNDROME; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN HOMEOSTASIS; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; RESPIRATORY BURST; REVIEW; SIGNAL TRANSDUCTION; STABLE EXPRESSION; STEM CELL SELF-RENEWAL; THROMBOCYTE; VASCULAR BIOLOGY; VASCULAR SMOOTH MUSCLE CELL; METABOLISM; NEOPLASM; OXIDATION REDUCTION REACTION;

ADAMTS1 PROTEIN; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CD47 ANTIGEN; CYSTEINE-RICH PROTEIN 61; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MARFAN SYNDROME; NEOPLASMS; OXIDATION-REDUCTION; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 85029812454     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2017.7140     Document Type: Review

References (318)

1. Abais JM, Xia M, Zhang Y, Boini KM, and Li PL. Redox regulation of NLRP3 inflammasomes: ROS as trigger or effector? Antioxid Redox Signal 22: 1111-1129, 2015.
2. Adams JC and Lawler J. The thrombospondins. Cold Spring Harb Perspect Biol 3: A009712, 2011.
3. Agah A, Kyriakides TR, Lawler J, and Bornstein P. The lack of thrombospondin-1 (TSP1) dictates the course of wound healing in double-TSP1/TSP2-null mice. Am J Pathol 161: 831-839, 2002.
4. Aird AL, Nevitt CD, Christian K, Williams SK, Hoying JB, and LeBlanc AJ. Adipose-derived stromal vascular fraction cells isolated from old animals exhibit reduced capacity to support the formation of microvascular networks. Exp Gerontol 63: 18-26, 2015.
5. Alblas J, Honing H, de Lavalette CR, Brown MH, Dijkstra CD, and van den Berg TK. Signal regulatory protein alpha ligation induces macrophage nitric oxide production through JAK/STAT-And phosphatidylinositol 3-kinase/Rac1/NAPDH oxidase/H2O2-dependent pathways. Mol Cell Biol 25: 7181-7192, 2005.
6. Arafat HA, Katakam AK, Chipitsyna G, Gong Q, Vancha AR, Gabbeta J, and Dafoe DC. Osteopontin protects the islets and beta-cells from interleukin-1 beta-mediated cytotoxicity through negative feedback regulation of nitric oxide. Endocrinology 148: 575-584, 2007.
7. Bai YP, Xiao S, Tang YB, Tan Z, Tang H, Ren Z, Zeng H, and Yang Z. Shear stress-mediated upregulation of GTP cyclohydrolase/tetrahydrobiopterin pathway ameliorates hypertension-related decline in reendothelialization capacity of endothelial progenitor cells. J Hypertens 35: 784-797, 2017.
8. Bancroft T, Bouaouina M, Roberts S, Lee M, Calderwood DA, Schwartz M, Simons M, Sessa WC, and Kyriakides TR. Up-regulation of thrombospondin-2 in Akt1-null mice contributes to compromised tissue repair due to abnormalities in fibroblast function. J Biol Chem 290: 409-422, 2015.
9. Barazi HO, Li Z, Cashel JA, Krutzsch HC, Annis DS, Mosher DF, and Roberts DD. Regulation of integrin function by CD47 ligands. Differential effects on avb3 and a4b1 integrin-mediated adhesion. J Biol Chem 277: 42859-42866, 2002.
10. Bauer EM, Qin Y, Miller TW, Bandle RW, Csanyi G, Pagano PJ, Bauer PM, Schnermann J, Roberts DD, and Isenberg JS. Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation. Cardiovasc Res 88: 471-481, 2010.
11. Bauer PM, Bauer EM, Rogers NM, Yao M, Feijoo- Cuaresma M, Pilewski JM, Champion HC, Zuckerbraun BS, Calzada MJ, and Isenberg JS. Activated CD47 promotes pulmonary arterial hypertension through targeting caveolin-1. Cardiovasc Res 93: 682-693, 2012.
12. Bonafe F, Guarnieri C, and Muscari C. Nitric oxide regulates multiple functions and fate of adult progenitor and stem cells. J Physiol Biochem 71: 141-153, 2015.
13. Bonnefoy A, Moura R, and Hoylaerts MF. The evolving role of thrombospondin-1 in hemostasis and vascular biology. Cell Mol Life Sci 65: 713-727, 2008.
14. Boo YC, Kim HJ, Song H, Fulton D, Sessa W, and Jo H. Coordinated regulation of endothelial nitric oxide synthase activity by phosphorylation and subcellular localization. Free Radic Biol Med 41: 144-153, 2006.
15. Borkham-Kamphorst E, Schaffrath C, Van de Leur E, Haas U, Tihaa L, Meurer SK, Nevzorova YA, Liedtke C, and Weiskirchen R. The anti-fibrotic effects of CCN1/CYR61 in primary portal myofibroblasts are mediated through induction of reactive oxygen species resulting in cellular senescence, apoptosis and attenuated TGF-beta signaling. Biochim Biophys Acta 1843: 902-914, 2014.
16. Bornstein P. Diversity of function is inherent in matricellular proteins: An appraisal of thrombospondin 1. J Cell Biol 130: 503-506, 1995.
17. Bouvet C, Gilbert LA, Girardot D, deBlois D, and Moreau P. Different involvement of extracellular matrix components in small and large arteries during chronic NO synthase inhibition. Hypertension 45: 432-437, 2005.
18. Buda V, Andor M, Petrescu L, Cristescu C, Baibata DE, Voicu M, Munteanu M, Citu I, Muntean C, Cretu O, and Tomescu MC. Perindopril induces TSP-1 expression in hypertensive patients with endothelial dysfunction in chronic treatment. Int J Mol Sci 18: pii: E348, 2017.
19. Buee L, Hof PR, Roberts DD, Delacourte A, Morrison JH, and Fillit HM. Immunohistochemical identification of thrombospondin in normal human brain and in Alzheimer's disease. Am J Pathol 141: 783-788, 1992.
20. Buono R, Vantaggiato C, Pisa V, Azzoni E, Bassi MT, Brunelli S, Sciorati C, and Clementi E. Nitric oxide sustains long-Term skeletal muscle regeneration by regulating fate of satellite cells via signaling pathways requiring Vangl2 and cyclic GMP. Stem Cells 30: 197-209, 2012.
21. Calzada MJ, Annis DS, Zeng B, Marcinkiewicz C, Banas B, Lawler J, Mosher DF, and Roberts DD. Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1. J Biol Chem 279: 41734- 41743, 2004.
22. Canfield AE, Farrington C, Dziobon MD, Boot-Handford RP, Heagerty AM, Kumar SN, and Roberts IS. The involvement of matrix glycoproteins in vascular calcification and fibrosis: An immunohistochemical study. J Pathol 196: 228-234, 2002.
23. Carlson CB, Lawler J, and Mosher DF. Structures of thrombospondins. Cell Mol Life Sci 65: 672-686, 2008.
24. Cevik O, Baykal AT, and Sener A. Platelets proteomic profiles of acute ischemic stroke patients. PLoS One 11: E0158287, 2016.
25. Chakraborty S, Karmakar K, and Chakravortty D. Cells producing their own nemesis: understanding methylglyoxal metabolism. IUBMB Life 66: 667-678, 2014.
26. Chanana B, Graf R, Koledachkina T, Pflanz R, and Vorbruggen G. AlphaPS2 integrin-mediated muscle attachment in Drosophila requires the ECM protein Thrombospondin. Mech Dev 124: 463-475, 2007.
27. Chen CC, Kim KH, and Lau LF. The matricellular protein CCN1 suppresses hepatocarcinogenesis by inhibiting compensatory proliferation. Oncogene 35: 1314-1323, 2016.
28. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V, and Lau LF. Cytotoxicity of TNFa is regulated by integrin-mediated matrix signaling. EMBO J 26: 1257- 1267, 2007.
29. Chen JK, Zhan YJ, Yang CS, and Tzeng SF. Oxidative stress-induced attenuation of thrombospondin-1 expression in primary rat astrocytes. J Cell Biochem 112: 59-70, 2011.
30. Choi KY, Kim DB, Kim MJ, Kwon BJ, Chang SY, Jang SW, ChoEJ, RhoTH, and Kim JH.Higher plasma thrombospondin- 1 levels in patients with coronary artery disease and diabetes mellitus. Korean Circ J 42: 100-106, 2012.
31. Chung J, Gao AG, and Frazier WA. Thrombspondin acts via integrin-Associated protein to activate the platelet integrin aIIbb3. J Biol Chem 272: 14740-14746, 1997.
32. Cingolani OH, Kirk JA, Seo K, Koitabashi N, Lee DI, Ramirez-Correa G, Bedja D, Barth AS, Moens AL, and Kass DA. Thrombospondin-4 is required for stretchmediated contractility augmentation in cardiac muscle. Circ Res 109: 1410-1414, 2011.
33. Cini C, Yip C, Attard C, Karlaftis V, Monagle P, Linden M, and Ignjatovic V. Differences in the resting platelet proteome and platelet releasate between healthy children and adults. J Proteomics 123: 78-88, 2015.
34. Colon S, Page-McCaw P, and Bhave G. Role of hypohalous acids in basement membrane homeostasis. Antioxid Redox Signal 2017 (in press).
35. Corsetti JP, Ryan D, Moss AJ, McCarthy J, Goldenberg I, Zareba W, and Sparks CE. Thrombospondin-4 polymorphism (A387P) predicts cardiovascular risk in postinfarction patients with high HDL cholesterol and C-reactive protein levels. Thromb Haemost 106: 1170-1178, 2011.
36. Csanyi G, Yao M, Rodriguez AI, Al Ghouleh I, Sharifi- Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, and Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 32: 2966-2973, 2012.
37. Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, and Bouck NP. CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells. J Cell Biol 138: 707-717, 1997.
38. DeLeon-Pennell KY, Tian Y, Zhang B, Cates CA, Iyer RP, Cannon P, Shah P, Aiyetan P, Halade GV, Ma Y, Flynn E, Zhang Z, Jin YF, Zhang H, and Lindsey ML. CD36 is a matrix metalloproteinase-9 substrate that stimulates neutrophil apoptosis and removal during cardiac remodeling. Circ Cardiovasc Genet 9: 14-25, 2016.
39. Della-Morte D, Beecham A, Dong C, Wang L, McClendon MS, Gardener H, Blanton SH, Sacco RL, and Rundek T. Association between variations in coagulation system genes and carotid plaque. J Neurol Sci 323: 93-98, 2012.
40. Denhardt DT, Burger EH, Kazanecki C, Krishna S, Semeins CM, and Klein-Nulend J. Osteopontin-deficient bone cells are defective in their ability to produce NO in response to pulsatile fluid flow. Biochem Biophys Res Commun 288: 448-453, 2001.
41. Devaux Y, Azuaje F, Vausort M, Yvorra C, and Wagner DR. Integrated protein network and microarray analysis to identify potential biomarkers after myocardial infarction. Funct Integr Genomics 10: 329-337, 2010.
42. Dikalov SI and Harrison DG. Methods for detection of mitochondrial and cellular reactive oxygen species. Antioxid Redox Signal 20: 372-382, 2014.
43. Dikalova AE, Gongora MC, Harrison DG, Lambeth JD, Dikalov S, and Griendling KK. Upregulation of Nox1 in vascular smooth muscle leads to impaired endotheliumdependent relaxation via eNOS uncoupling. Am J Physiol Heart Circ Physiol 299: H673-H679, 2010.
44. Dong R, Wang X, Wang H, Liu Z, Liu J, and Saavedra JE. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells. Biomed Pharmacother 88: 367-373, 2017.
45. Dong XQ, Yu WH, Zhu Q, Cheng ZY, Chen YH, Lin XF, Ten XL, Tang XB, and Chen J. Changes in plasma thrombospondin-1 concentrations following acute intracerebral hemorrhage. Clin Chim Acta 450: 349-355, 2015.
46. Dorahy DJ, Thorne RF, Fecondo JV, and Burns GF. Stimulation of platelet activation and aggregation by a carboxyl-Terminal peptide from thrombospondin binding to the integrin-Associated protein receptor. J Biol Chem 272: 1323-1330, 1997.
47. Dreieicher E, Beck KF, Lazaroski S, Boosen M, Tsalastra- Greul W, Beck M, Fleming I, Schaefer L, and Pfeilschifter J. Nitric oxide inhibits glomerular TGF-beta signaling via SMOC-1. J Am Soc Nephrol 20: 1963-1974, 2009.
48. Duquette M, Nadler M, Okuhara D, Thompson J, Shuttleworth T, and Lawler J. Members of the thrombospondin gene family bind stromal interaction molecule 1 and regulate calcium channel activity. Matrix Biol 37: 15-24, 2014.
49. Eroglu C, Allen NJ, Susman MW, O'Rourke NA, Park CY, Ozkan E, Chakraborty C, Mulinyawe SB, Annis DS, Huberman AD, Green EM, Lawler J, Dolmetsch R, Garcia KC, Smith SJ, Luo ZD, Rosenthal A, Mosher DF, and Barres BA. Gabapentin receptor alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS synaptogenesis. Cell 139: 380-392, 2009.
50. Fatma N, Kubo E, Toris CB, Stamer WD, Camras CB, and Singh DP. PRDX6 attenuates oxidative stress-And TGFbeta-induced abnormalities of human trabecular meshwork cells. Free Radic Res 43: 783-795, 2009.
51. Faulcon LM, Fu Z, Dulloor P, Barron-Casella E, Savage W, Jennings JM, Van Eyk JE, Debaun M, Casella JF, and Everett A. Thrombospondin-1 and L-selectin are associated with silent cerebral infarct in children with sickle cell anaemia. Br J Haematol 162: 421-424, 2013.
52. Favier J, Germain S, Emmerich J, Corvol P, and Gasc JM. Critical overexpression of thrombospondin 1 in chronic leg ischaemia. J Pathol 207: 358-366, 2005.
53. Fei P, Zaitoun I, Farnoodian M, Fisk DL, Wang S, Sorenson CM, and Sheibani N. Expression of thrombospondin- 1 modulates the angioinflammatory phenotype of choroidal endothelial cells. PLoS One 9: E116423, 2014.
54. Floquet N, Dedieu S, Martiny L, Dauchez M, and Perahia D. Human thrombospondin's (TSP-1) C-Terminal domain opens to interact with the CD-47 receptor: A molecular modeling study. Arch Biochem Biophys 478: 103-109, 2008.
55. Forstermann U and Sessa WC. Nitric oxide synthases: Regulation and function. Eur Heart J a 33: 829-837, 37a- 37d, 2012.
56. Frazier EP, Isenberg JS, Shiva S, Zhao L, Schlesinger P, Dimitry J, Abu-Asab MS, Tsokos M, Roberts DD, and Frazier WA. Age-dependent regulation of skeletal muscle mitochondria by the thrombospondin-1 receptor CD47. Matrix Biol 30: 154-161, 2011.
57. Frolova EG, Sopko N, Blech L, Popovic ZB, Li J, Vasanji A, Drumm C, Krukovets I, Jain MK, Penn MS, Plow EF, and Stenina OI. Thrombospondin-4 regulates fibrosis and remodeling of the myocardium in response to pressure overload. FASEB J 26: 2363-2373, 2012.
58. Gao A-G, Lindberg FP, Finn MB, Blystone SD, Brown EJ, and Frazier WA. Integrin-Associated protein is a receptor for the C-Terminal domain of thrombospondin. J Biol Chem 271: 21-24, 1996.
59. Gao JB, Tang WD, Wang HX, and Xu Y. Predictive value of thrombospondin-1 for outcomes in patients with acute ischemic stroke. Clin Chim Acta 450: 176-180, 2015.
60. Gao Q, Chen K, Gao L, Zheng Y, and Yang YG. Thrombospondin-1 signaling through CD47 inhibits cell cycle progression and induces senescence in endothelial cells. Cell Death Dis 7: E2368, 2016.
61. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, and Schwartz SM. Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 92: 1686-1696, 1993.
62. Gliemann L, Buess R, Nyberg M, Hoppeler H, Odriozola A, Thaning P, Hellsten Y, Baum O, and Mortensen SP. Capillary growth, ultrastructure remodelling and exercise training in skeletal muscle of essential hypertensive patients. Acta Physiol (Oxf) 214: 210-220, 2015.
63. Gonzalez-Domenech CM and Munoz-Chapuli R. Molecular evolution of nitric oxide synthases in metazoans. Comp Biochem Physiol Part D Genomics Proteomics 5: 295-301, 2010.
64. Gordan JD, Thompson CB, and Simon MC. HIF and c- Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 12: 108-113, 2007.
65. Gornicka A, Morris-Stiff G, Thapaliya S, Papouchado BG, Berk M, and Feldstein AE. Transcriptional profile of genes involved in oxidative stress and antioxidant defense in a dietary murine model of steatohepatitis. Antioxid Redox Signal 15: 437-445, 2011.
66. Greiner R, Palinkas Z, Basell K, Becher D, Antelmann H, Nagy P, and Dick TP. Polysulfides link H2S to protein thiol oxidation. Antioxid Redox Signal 19: 1749-1765, 2013.
67. Guo H, Cai CQ, Schroeder RA, and Kuo PC. Osteopontin is a negative feedback regulator of nitric oxide synthesis in murine macrophages. J Immunol 166: 1079-1086, 2001.
68. Guo N, Zabrenetzky VS, Chandrasekaran L, Sipes JM, Lawler J, Krutzsch HC, and Roberts DD. Differential roles of protein kinase C and pertussis toxin-sensitive Gbinding proteins in modulation of melanoma cell proliferation and motility by thrombospondin-1. Cancer Res 58: 3154-3162, 1998.
69. Gutierrez LS, Ling J, Nye D, Papathomas K, and Dickinson C. Thrombospondin peptide ABT-898 inhibits inflammation and angiogenesis in a colitis model. World J Gastroenterol 21: 6157-6166, 2015.
70. Hanatani S, Izumiya Y, Takashio S, Kimura Y, Araki S, Rokutanda T, Tsujita K, Yamamoto E, Tanaka T, Yamamuro M, Kojima S, Tayama S, Kaikita K, Hokimoto S, and Ogawa H. Circulating thrombospondin-2 reflects disease severity and predicts outcome of heart failure with reduced ejection fraction. Circ J 78: 903-910, 2014.
71. Hein L, Stevens ME, Barsh GS, Pratt RE, Kobilka BK, and Dzau VJ. Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A 94: 6391- 6396, 1997.
72. Hernanz R, Martinez-Revelles S, Palacios R, Martin A, Cachofeiro V, Aguado A, Garcia-Redondo L, Barrus MT, de Batista PR, Briones AM, Salaices M, and Alonso MJ. Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension. Br J Pharmacol 172: 3159-3176, 2015.
73. Hirano Y, Aziz M, Yang WL, Ochani M, and Wang P. Neutralization of Osteopontin Ameliorates Acute Lung Injury Induced by Intestinal Ischemia-Reperfusion. Shock 46: 431-438, 2016.
74. Ho C, Lee PH, Huang WJ, Hsu YC, Lin CL, and Wang JY. Methylglyoxal-induced fibronectin gene expression through Ras-mediated NADPH oxidase activation in renal mesangial cells. Nephrology (Carlton) 12: 348- 356, 2007.
75. Hohenstein B, Daniel C, Hausknecht B, Boehmer K, Riess R, Amann KU, and Hugo CP. Correlation of enhanced thrombospondin-1 expression, TGF-beta signalling and proteinuria in human type-2 diabetic nephropathy. Nephrol Dial Transplant 23: 3880-3887, 2008.
76. Hohenstein B, Daniel C, Wittmann S, and Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-beta activation and matrix accumulation in experimental glomerulonephritis. Nephrol Dial Transplant 23: 3427-3436, 2008.
77. Hoier B, Nordsborg N, Andersen S, Jensen L, Nybo L, Bangsbo J, and Hellsten Y. Pro-And anti-Angiogenic factors in human skeletal muscle in response to acute exercise and training. J Physiol 590: 595-606, 2012.
78. Hoier B, Walker M, Passos M, Walker PJ, Green A, Bangsbo J, Askew CD, and Hellsten Y. Angiogenic response to passive movement and active exercise in individuals with peripheral arterial disease. J Appl Physiol (1985) 115: 1777-1787, 2013.
79. Holwerda KM, Burke SD, Faas MM, Zsengeller Z, Stillman IE, Kang PM, van Goor H, McCurley A, Jaffe IZ, Karumanchi SA, and Lely AT. Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol 25: 717-725, 2014.
80. Huang CL, Jong YS, Wu YW, Wang WJ, Hsieh AR, Chao CL, Chen WJ, and Yang WS. Association of plasma thrombospondin-1 level with cardiovascular disease and mortality in hemodialysis patients. Acta Cardiol Sin 31: 113-119, 2015.
81. Huang H, Du W, and Brekken RA. Extracellular matrix induction of intracellular reactive oxygen species. Antioxid Redox Signal 2017 (in press).
82. Hwang SM, Lopez CA, Heck DE, Gardner CR, Laskin DL, Laskin JD, and Denhardt DT. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 269: 711-715, 1994.
83. Ida T, Sawa T, Ihara H, Tsuchiya Y, Watanabe Y, Kumagai Y, Suematsu M, Motohashi H, Fujii S, Matsunaga T, Yamamoto M, Ono K, Devarie-Baez NO, Xian M, Fukuto JM, and Akaike T. Reactive cysteine persulfides and S-polythiolation regulate oxidative stress and redox signaling. Proc Natl Acad Sci U S A 111: 7606-7611, 2014.
84. Isenberg JS, Annis DS, Pendrak ML, Ptaszynska M, Frazier WA, Mosher DF, and Roberts DD. Differential interactions of thrombospondin-1, -2, and -4 with CD47 and effects on cGMP signaling and ischemic injury responses. J Biol Chem 284: 1116-1125, 2009.
85. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu- Asab M, Tsokos M, Kuppusamy P, Wink DA, Krishna MC, and Roberts DD. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 109: 1945-1952, 2007.
86. Isenberg JS, Hyodo F, Pappan LK, Abu-Asab M, Tsokos M, Krishna MC, Frazier WA, and Roberts DD. Blocking thrombospondin-1/CD47 signaling alleviates deleterious effects of aging on tissue responses to ischemia. Arterioscler Thromb Vasc Biol 27: 2582-2588, 2007.
87. Isenberg JS, Jia Y, Fukuyama J, Switzer CH, Wink DA, and Roberts DD. Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake. J Biol Chem 282: 15404-15415, 2007.
88. Isenberg JS, Martin-Manso G, Maxhimer JB, and Roberts DD. Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-Angiogenic therapies. Nat Rev Cancer 9: 182-194, 2009.
89. Isenberg JS, Maxhimer JB, Powers P, Tsokos M, Frazier WA, and Roberts DD. Treatment of ischemia/reperfusion injury by limiting thrombospondin-1/CD47 signaling. Surgery 144: 752-761, 2008.
90. Isenberg JS, Pappan LK, Romeo MJ, Abu-Asab M, Tsokos M, Wink DA, Frazier WA, and Roberts DD. Blockade of thrombospondin-1-CD47 interactions prevents necrosis of full thickness skin grafts. Ann Surg 247: 180-190, 2008.
91. Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J, Frazier WA, and Roberts DD.Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 28: 110-119, 2009.
92. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, and Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 281: 26069-26080, 2006.
93. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, and Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMPdependent manner. Proc Natl Acad Sci U S A 102: 13141- 13146, 2005.
94. Isenberg JS, Romeo MJ, Abu-Asab M, Tsokos M, Oldenborg A, Pappan L, Wink DA, Frazier WA, and Roberts DD. Increasing survival of ischemic tissue by targeting CD47. Circ Res 100: 712-720, 2007.
95. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J, Rick ME, Wink DA, Frazier WA, and Roberts DD. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/cGMP signaling. Blood 111: 613-623, 2008.
96. Isenberg JS, Wink DA, and Roberts DD. Thrombospondin- 1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 71: 785-793, 2006.
97. Isenberg JS, Yu C, and Roberts DD. Differential effects of ABT-510 and a CD36-binding peptide derived from the type 1 repeats of thrombospondin-1 on fatty acid uptake, nitric oxide signaling, and caspase activation in vascular cells. Biochem Pharmacol 75: 875-882, 2008.
98. Jacob SA, Novelli EM, Isenberg JS, Garrett ME, Chu Y, Soldano K, Ataga KI, Telen MJ, Ashley-Koch A, Gladwin MT, Zhang Y, and Kato GJ. Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. Am J Hematol 92: E31-E34, 2017.
99. Jalnapurkar S, Singh S, Devi MR, Limaye L, and Kale V. Nitric oxide has contrasting age-dependent effects on the functionality of murine hematopoietic stem cells. Stem Cell Res Ther 7: 171, 2016.
100. Ji K, de Carvalho LP, Bi X, Seneviratnankn A, Bhakoo K, Chan M, and Yau Li SF. Highly sensitive and quantitative human thrombospondin-1 detection by an M55 aptasensor and clinical validation in patients with atherosclerotic disease. Biosens Bioelectron 55: 405-411, 2014.
101. Jin G, Tsuji K, Xing C, Yang YG, Wang X, Lo EH. CD47 gene knockout protects against transient focal cerebral ischemia in mice. Exp Neurol 217: 165-70, 2009.
102. Juric V, Chen CC, and Lau LF. Fas-mediated apoptosis is regulated by the extracellularmatrix proteinCCN1 (CYR61) in vitro and in vivo. Mol Cell Biol 29: 3266-3279, 2009.
103. Juric V, Chen CC, and Lau LF. TNFalpha-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release. PLoS One 7: E31303, 2012.
104. Kaiser R, Frantz C, Bals R, and Wilkens H. The role of circulating thrombospondin-1 in patients with precapillary pulmonary hypertension. Respir Res 17: 96, 2016.
105. Kanagy NL, Szabo C, and Papapetropoulos A. Vascular biology of hydrogen sulfide. Am J Physiol Cell Physiol 312: C537-C549, 2017.
106. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 37: 601-611, 2001.
107. Kang X, Wei X, Jiang L, Niu C, Zhang J, Chen S, and Meng D. Nox2 and Nox4 regulate self-renewal of murine induced-pluripotent stem cells. IUBMB Life 68: 963-970, 2016.
108. Kanno S, Hirano S, Sagi M, Chiba S, Takeshita H, Ikawa T, Ichiba K, Nagai T, Takada M, Sakamoto K, and Mukai T. Sulfide induces apoptosis and Rho kinase-dependent cell blebbing in Jurkat cells. Arch Toxicol 87: 1245-1256, 2013.
109. Kaur S, Chang T, Singh SP, Lim L, Mannan P, Garfield SH, Pendrak ML, Soto-Pantoja DR, Rosenberg AZ, Jin S, and Roberts DD. CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. J Immunol 193: 3914-3924, 2014.
110. Kaur S, Elkahloun AG, Singh SP, Chen QR, Meerzaman DM, Song T, Manu N, Wu W, Mannan P, Garfield SH, and Roberts DD. A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer. Oncotarget 7: 10133-52, 2016.
111. Kaur S, Kuznetsova SA, Pendrak ML, Sipes JM, Romeo MJ, Li Z, Zhang L, and Roberts DD. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem 286: 14991-15002, 2011.
112. Kaur S, Martin-Manso G, Pendrak ML, Garfield SH, Isenberg JS, and Roberts DD. Thrombospondin-1 inhibits vascular endothelial growth factor receptor-2 signaling by disrupting its association with CD47. J Biol Chem 285: 38923-38932, 2010.
113. Kaur S and Roberts DD. Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling. Int J Biochem Cell Biol 81: 184-194, 2016.
114. Kaur S, Soto-Pantoja DR, Stein EV, Liu C, Elkahloun AG, Pendrak ML, Nicolae A, Singh SP, Nie Z, Levens D, Isenberg JS, and Roberts DD. Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-Myc and other stem cell transcription factors. Sci Rep 3: 1673, 2013.
115. Kimura Y, Izumiya Y, Hanatani S, Yamamoto E, Kusaka H, Tokitsu T, Takashio S, Sakamoto K, Tsujita K, Tanaka T, Yamamuro M, Kojima S, Tayama S, Kaikita K, Hokimoto S, and Ogawa H. High serum levels of thrombospondin-2 correlate with poor prognosis of patients with heart failure with preserved ejection fraction. Heart Vessels 31: 52-59, 2016.
116. Kirk R, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, Rahmel AO, Stehlik J, and Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Fourteenth Pediatric Heart Transplantation Report-2011. J Heart Lung Transplant 30: 1095-1103, 2011.
117. Kuebler WM.What mediates the effects of thrombospondin- 1 in pulmonary hypertension? New evidence for a dualpronged role of CD47. Cardiovasc Res 113: 3-5, 2017.
118. Kumar R, Mickael C, Kassa B, Gebreab L, Robinson JC, Koyanagi DE, Sanders L, Barthel L, Meadows C, Fox D, Irwin D, Li M, McKeon BA, Riddle S, Dale Brown R, Morgan LE, Evans CM, Hernandez-Saavedra D, Bandeira A, Maloney JP, Bull TM, Janssen WJ, Stenmark KR, Tuder RM, and Graham BB. TGF-beta activation by bone marrow-derived thrombospondin-1 causes Schistosomaand hypoxia-induced pulmonary hypertension. Nat Commun 8: 15494, 2017.
119. Kundu S, Pushpakumar S, Khundmiri SJ, and Sen U. Hydrogen sulfide mitigates hyperglycemic remodeling via liver kinase B1-Adenosine monophosphate-Activated protein kinase signaling. Biochim Biophys Acta 1843: 2816- 2826, 2014.
120. Kunkemoeller B and Kyriakides TR. Redox signaling in diabetic wound healing regulates extracellular matrix deposition. Antioxid Redox Signal 2017 (in press).
121. Kuntz S, Kunz C, and Rudloff S. Carbonyl compounds methylglyoxal and glyoxal affect interleukin-8 secretion in intestinal cells by superoxide anion generation and activation of MAPK p38. Mol Nutr Food Res 54: 1458- 1467, 2010.
122. Kvansakul M, Adams JC, and Hohenester E. Structure of a thrombospondin C-Terminal fragment reveals a novel calcium core in the type 3 repeats. EMBO J 23: 1223- 1233, 2004.
123. Kwong LS, Brown MH, Barclay AN, and Hatherley D. Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity- implications for engraftment of human cells. Immunology 143: 61-67, 2014.
124. Labrousse-Arias D, Castillo-Gonzalez R, Rogers NM, Torres-Capelli M, Barreira B, Aragones J, Cogolludo A, Isenberg JS, and Calzada MJ. HIF-2alpha-mediated induction of pulmonary thrombospondin-1 contributes to hypoxia-driven vascular remodelling and vasoconstriction. Cardiovasc Res 109: 115-130, 2016.
125. Labrousse-Arias D, Martínez-Ruiz A, and Calzada MJ. Hypoxia and redox signaling on extracellular matrix remodeling: from the mechanisms to the pathological implications. Antioxid Redox Signal 2017 (in press).
126. Lario S, Bescos M, Campos B, Mur C, Luque P, Alvarez R, and Campistol JM. Thrombospondin-1 mRNA expression in experimental kidney transplantation with heart-beating and non-heart-beating donors. J Nephrol 20: 588-595, 2007.
127. Lau LF. CCN1/CYR61: The very model of a modern matricellular protein. Cell Mol Life Sci 68: 3149-3163, 2011.
128. Lawler J, Sunday M, Thibert V, Duquette M, George EL, Rayburn H, and Hynes RO. Thrombospondin-1 is required for normal murine pulmonary homeostasis and its absence causes pneumonia. J Clin Invest 101: 982-992, 1998.
129. LeBlanc AJ and Kelm NQ. Thrombospondin-1, free radicals, and the coronary microcirculation: The aging conundrum. Antioxid Redox Signal 2017 (in press).
130. Leclair P and Lim CJ. CD47-independent effects mediated by the TSP-derived 4N1K peptide. PLoS One 9: E98358, 2014.
131. Lee HJ, Feliers D, Mariappan MM, Sataranatarajan K, Choudhury GG, Gorin Y, and Kasinath BS. Tadalafil integrates nitric oxide-hydrogen sulfide signaling to inhibit high glucose-induced matrix protein synthesis in podocytes. J Biol Chem 290: 12014-12026, 2015.
132. Lee HJ, Mariappan MM, Feliers D, Cavaglieri RC, Sataranatarajan K, Abboud HE, Choudhury GG, and Kasinath BS. Hydrogen sulfide inhibits high glucose-induced matrix protein synthesis by activating AMP-Activated protein kinase in renal epithelial cells. J Biol Chem 287: 4451-4461, 2012.
133. Lee JH, Bhang DH, Beede A, Huang TL, Stripp BR, Bloch KD, Wagers AJ, Tseng YH, Ryeom S, and Kim CF. Lung stem cell differentiation in mice directed by endo-Thelial cells via a BMP4-NFATc1-Thrombospondin-1 axis. Cell 156: 440-455, 2014.
134. Lee R and Britz-McKibbin P. Metabolomic studies of radiation-induced apoptosis of human leukocytes by capillary electrophoresis-mass spectrometry and flow cytometry: Adaptive cellular responses to ionizing radiation. Electrophoresis 31: 2328-2337, 2010.
135. Lee TK, Cheung VC, Lu P, Lau EY, Ma S, Tang KH, Tong M, Lo J, and Ng IO. Blockade of CD47-mediated cathepsin S/protease-Activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60: 179-191, 2014.
136. Legrand C, Morandi V, Mendelovitz S, Shaked H, Hartman JR, and Panet A. Selective inhibition of platelet macroaggregate formation by a recombinant heparinbinding domain of human thrombospondin. Arterioscler Thromb 14: 1784-1791, 1994.
137. Li XJ, Goodwin CB, Nabinger SC, Richine BM, Yang Z, HanenbergH, OhnishiH, Matozaki T, FengGS, and Chan RJ. Protein-Tyrosine phosphatase Shp2 positively regulates macrophage oxidative burst. J Biol Chem 290: 3894-3909, 2015.
138. Li Y, Qi X, Tong X, and Wang S. Thrombospondin 1 activates the macrophage Toll-like receptor 4 pathway. Cell Mol Immunol 10: 506-512, 2013.
139. Lin TN, Kim GM, Chen JJ, Cheung WM, He YY, and Hsu CY. Differential regulation of thrombospondin-1 and thrombospondin-2 after focal cerebral ischemia/reperfusion. Stroke 34: 177-186, 2003.
140. Lin X, Zhang F, Bradbury CM, Kaushal A, Li L, Spitz DR, Aft RL, and Gius D. 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res 63: 3413-3417, 2003.
141. Lin Y, Manning PT, Jia J, Gaut JP, Xiao Z, Capoccia BJ, Chen CC, Hiebsch RR, Upadhya G, Mohanakumar T, Frazier WA, and Chapman WC. CD47 blockade reduces ischemia-reperfusion injury and improves outcomes in a rat kidney transplant model. Transplantation 98: 394-401, 2014.
142. Lindsey ML, Zouein FA, Tian Y, Padmanabhan Iyer R, and de Castro Bras LE. Osteopontin is proteolytically processed by matrix metalloproteinase 9. Can J Physiol Pharmacol 93: 879-886, 2015.
143. Liu AY, Zheng H, and Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol 37: 150-156, 2014.
144. Liu J, Hughes TE, and Sessa WC. The first 35 amino acids and fatty acylation sites determine the molecular targeting of endothelial nitric oxide synthase into the Golgi region of cells: A green fluorescent protein study. J Cell Biol 137: 1525-1535, 1997.
145. Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, Willingham S, Howard M, Prohaska S, Volkmer J, Chao M, Weissman IL, and Majeti R. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One 10: E0137345, 2015.
146. Liu Y, Yang R, Liu X, Zhou Y, Qu C, Kikuiri T, Wang S, Zandi E, Du J, Ambudkar IS, and Shi S. Hydrogen sulfide maintains mesenchymal stem cell function and bone homeostasis via regulation of Ca(2+) channel sulfhydration. Cell Stem Cell 15: 66-78, 2014.
147. Liu YX, Wang J, Guo J, Wu J, Lieberman HB, and Yin Y. DUSP1 is controlled by p53 during the cellular response to oxidative stress. Mol Cancer Res 6: 624-633, 2008.
148. Lo J, Lau EY, So FT, Lu P, Chan VS, Cheung VC, Ching RH, Cheng BY, Ma MK, Ng IO, and Lee TK. Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. Liver Int 36: 737-745, 2016.
149. Lubos E, Loscalzo J, and Handy DE. Glutathione peroxidase-1 in health and disease: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal 15: 1957-1997, 2011.
150. MacLauchlan S, Yu J, Parrish M, Asoulin TA, Schleicher M, Krady MM, Zeng J, Huang PL, Sessa WC, and Kyriakides TR. Endothelial nitric oxide synthase controls the expression of the angiogenesis inhibitor thrombospondin 2. Proc Natl Acad Sci U S A 108: E1137-E1145, 2011.
151. Maghzal GJ, Cergol KM, Shengule SR, Suarna C, Newington D, Kettle AJ, Payne RJ, and Stocker R. Assessment of myeloperoxidase activity by the conversion of hydroethidine to 2-chloroethidium. J Biol Chem 289: 5580- 5595, 2014.
152. Maile LA, Allen LB, Hanzaker CF, Gollahon KA, Dunbar P, and Clemmons DR. Glucose regulation of thrombospondin and its role in the modulation of smooth muscle cell proliferation. Exp Diabetes Res 2010: pii: 617052, 2010.
153. Makni-Maalej K, Chiandotto M, Hurtado-Nedelec M, Bedouhene S, Gougerot-Pocidalo MA, Dang PM, and El- Benna J. Zymosan induces NADPH oxidase activation in human neutrophils by inducing the phosphorylation of p47phox and the activation of Rac2: involvement of protein tyrosine kinases, PI3Kinase, PKC, ERK1/2 and p38MAPkinase. Biochem Pharmacol 85: 92-100, 2013.
154. Mariggio MA, Minunno V, Riccardi S, Santacroce R, De Rinaldis P, and Fumarulo R. Sulfide enhancement of PMN apoptosis. Immunopharmacol Immunotoxicol 20: 399- 408, 1998.
155. Martin-Manso G, Galli S, Ridnour LA, Tsokos M, Wink DA, and Roberts DD. Thrombospondin-1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity by differentiated U937 cells. Cancer Res 68: 7090-7099, 2008.
156. Martinelli R, Newton G, Carman CV, Greenwood J, and Luscinskas FW. Novel role of CD47 in rat microvascular endothelium: signaling and regulation of T-cell transendothelial migration. Arterioscler Thromb Vasc Biol 33: 2566-2576, 2013.
157. Martinez-Revelles S, Caracuel L, Marquez-Martin A, Dantas A, Oliver E, D'Ocon P, and Vila E. Increased endothelin-1 vasoconstriction in mesenteric resistance arteries after superior mesenteric ischaemia-reperfusion. Br J Pharmacol 165: 937-950, 2012.
158. Matlung HL, Szilagyi K, Barclay NA, and van den Berg TK. The CD47-SIRPalpha signaling axis as an innate immune checkpoint in cancer. Immunol Rev 276: 145- 164, 2017.
159. Matsuo Y, Tanaka M, Yamakage H, Sasaki Y, Muranaka K, Hata H, Ikai I, Shimatsu A, Inoue M, Chun TH, and Satoh-Asahara N. Thrombospondin 1 as a novel biological marker of obesity and metabolic syndrome. Metabolism 64: 1490-1499, 2015.
160. Maxhimer JB, Shih HB, Isenberg JS, Miller TW, and Roberts DD. Thrombospondin-1-CD47 blockade following ischemia reperfusion injury is tissue protective. Plast Reconstr Surg 124: 1880-1889, 2009.
161. Maxhimer JB, Soto-Pantoja DR, Ridnour LA, Shih HB, DeGraff WG, Tsokos M, Wink DA, Isenberg JS, and Roberts DD. Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling. Sci Transl Med 1: 3ra7, 2009.
162. Mikula-Pietrasik J, Sosinska P, Janus J, Rubis B, Brewinska-Olchowik M, Piwocka K, and Ksiazek K. Bystander senescence in human peritoneal mesothelium and fibroblasts is related to thrombospondin-1-dependent activation of transforming growth factor-beta1. Int J Biochem Cell Biol 45: 2087-2096, 2013.
163. Miller TW, Isenberg JS, and Roberts DD. Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase. Br J Pharmacol 159: 1542-1547, 2010.
164. Miller TW, Isenberg JS, Shih HB, Wang Y, and Roberts DD. Amyloid-beta inhibits No-cGMP signaling in a CD36-And CD47-dependent manner. PLoS One 5: E15686, 2010.
165. Miller TW, Kaur S, Ivins-O'Keefe K, and Roberts DD. Thrombospondin-1 is a CD47-dependent endogenous inhibitor of hydrogen sulfide signaling in T cell activation. Matrix Biol 32: 316-324, 2013.
166. Miller TW, Soto-Pantoja DR, Schwartz AL, Sipes JM, DeGraff WG, Ridnour LA, Wink DA, and Roberts DD. CD47 globally regulates metabolic pathways that control resistance to ionizing radiation. J Biol Chem 290: 24858- 24874, 2015.
167. Miller TW, Wang EA, Gould S, Stein EV, Kaur S, Lim L, Amarnath S, Fowler DH, and Roberts DD. Hydrogen sulfide is an endogenous potentiator of T cell activation. J Biol Chem 287: 4211-4221, 2012.
168. Miyamoto K, Miyamoto T, Kato R, Yoshimura A, Motoyama N, and Suda T. FoxO3a regulates hematopoietic homeostasis through a negative feedback pathway in conditions of stress or aging. Blood 112: 4485-4493, 2008.
169. Morrish F, Isern N, Sadilek M, Jeffrey M, and Hockenbery DM. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28: 2485-2491, 2009.
170. Mosher DF and Adams JC. Adhesion-modulating/matricellular ECM protein families: A structural, functional and evolutionary appraisal. Matrix Biol 31: 155- 161, 2012.
171. Murphy-Ullrich JE, Pallero MA, Boerth N, Greenwood JA, Lincoln TM, and Cornwell TL. Cyclic GMPdependent protein kinase is required for thrombospondin and tenascin mediated focal adhesion disassembly. J Cell Sci 109: 2499-2508, 1996.
172. Murphy-Ullrich JE and Sage EH. Revisiting the matricellular concept. Matrix Biol 37: 1-14, 2014.
173. Mustafa AK, Gadalla MM, Sen N, Kim S, Mu W, Gazi SK, Barrow RK, Yang G, Wang R, and Snyder SH. H2S signals through protein S-sulfhydration. Sci Signal 2: Ra72, 2009.
174. Mustafa AK, Gadalla MM, and Snyder SH. Signaling by gasotransmitters. Sci Signal 2: Re2, 2009.
175. Nagaraju GP, Dontula R, El-Rayes BF, and Lakka SS. Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis 35: 967-973, 2014.
176. Naito T, Masaki T, Nikolic-Paterson DJ, Tanji C, Yorioka N, and Kohno N. Angiotensin II induces thrombospondin- 1 production in human mesangial cells via p38 MAPK and JNK: A mechanism for activation of latent TGF-beta1. Am J Physiol Renal Physiol 286: F278-F287, 2004.
177. Namin SM, Nofallah S, Joshi MS, Kavallieratos K, and Tsoukias NM. Kinetic analysis of DAF-FM activation by NO: Toward calibration of a NO-sensitive fluorescent dye. Nitric Oxide 28: 39-46, 2013.
178. Narizhneva NV, Byers-Ward VJ, Quinn MJ, Zidar FJ, Plow EF, Topol EJ, and Byzova TV. Molecular and functional differences induced in thrombospondin-1 by the single nucleotide polymorphism associated with the risk of premature, familial myocardial infarction. J Biol Chem 279: 21651-21657, 2004.
179. Nastase M-V, Janicova A, Wygrecka M, and Schaefer L. Signaling at the crossroads: matrix-derived proteoglycan and reactive oxygen species signaling. Antioxid Redox Signal 2017 (in press).
180. Nathan C, Srimal S, Farber C, Sanchez E, Kabbash L, Asch A, Gailit J, and Wright SD. Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 109: 1341-1349, 1989.
181. Navarathna DH, Stein EV, Lessey-Morillon EC, Nayak D, Martin-Manso G, and Roberts DD. CD47 Promotes protective innate and adaptive immunity in a mouse model of disseminated candidiasis. PLoS One 10: E0128220, 2015.
182. Navarro-Sobrino M, Rosell A, Hernandez-Guillamon M, Penalba A, Boada C, Domingues-Montanari S, Ribo M, Alvarez-Sabin J, and Montaner J. A large screening of angiogenesis biomarkers and their association with neurological outcome after ischemic stroke. Atherosclerosis 216: 205-211, 2011.
183. Nevitt C, McKenzie G, Christian K, Austin J, Hencke S, Hoying J, and LeBlanc A. Physiological levels of thrombospondin-1 decrease NO-dependent vasodilation in coronary microvessels from aged rats. Am J Physiol Heart Circ Physiol 310: H1842-H1850, 2016.
184. Nogueira-Pedro A, Dias CC, Regina H, Segreto C, Addios PC, Lungato L, D'Almeida V, Barros CC, Higa EM, Buri MV, Ferreira AT, and Paredes-Gamero EJ. Nitric oxideinduced murine hematopoietic stem cell fate involves multiple signaling proteins, gene expression, and redox modulation. Stem Cells 32: 2949-2960, 2014.
185. Novelli EM, Kato GJ, Ragni MV, Zhang Y, Hildesheim ME, Nouraie M, Barge S, Meyer MP, Hassett AC, Gordeuk VR, Gladwin MT, and Isenberg JS. Plasma thrombospondin-1 is increased during acute sickle cell vaso-occlusive events and associated with acute chest syndrome, hydroxyurea therapy, and lower hemolytic rates. Am J Hematol 87: 326-330, 2012.
186. Olfert IM, Breen EC, Gavin TP, and Wagner PD. Temporal thrombospondin-1 mRNA response in skeletal muscle exposed to acute and chronic exercise. Growth Factors 24: 253-259, 2006.
187. Oller J, Mendez-Barbero N, Ruiz EJ, Villahoz S, Renard M, Canelas LI, Briones AM, Alberca R, Lozano-Vidal N, Hurle MA, Milewicz D, Evangelista A, Salaices M, Nistal JF, Jimenez-Borreguero LJ, De Backer J, Campanero MR, and Redondo JM. Nitric oxide mediates aortic disease in mice deficient in the metalloprotease Adamts1 and in a mouse model of Marfan syndrome. Nat Med 23: 200-212, 2017.
188. Osada-Oka M, Ikeda T, Akiba S, and Sato T. Hypoxia stimulates the autocrine regulation of migration of vascular smooth muscle cells via HIF-1alpha-dependent expression of thrombospondin-1. J Cell Biochem 104: 1918-1926, 2008.
189. Paradis P, Dali-Youcef N, Paradis FW, Thibault G, and Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc Natl Acad Sci U S A 97: 931-936, 2000.
190. Patouraux S, Rousseau D, Rubio A, Bonnafous S, Lavallard VJ, Lauron J, Saint-Paul MC, Bailly-Maitre B, Tran A, Crenesse D, and Gual P. Osteopontin deficiency aggravates hepatic injury induced by ischemia-reperfusion in mice. Cell Death Dis 5: E1208, 2014.
191. Patterson AD, Li H, Eichler GS, Krausz KW, Weinstein JN, Fornace AJ Jr., Gonzalez FJ, and Idle JR. UPLC-ESITOFMS- based metabolomics and gene expression dynamics inspector self-organizing metabolomic maps as tools for understanding the cellular response to ionizing radiation. Anal Chem 80: 665-674, 2008.
192. Persy VP, Verhulst A, Ysebaert DK, De Greef KE, and De Broe ME. Reduced postischemic macrophage infiltration and interstitial fibrosis in osteopontin knockout mice. Kidney Int 63: 543-553, 2003.
193. Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, Chai V, Chen H, Lee V, House V, Vigo NT, Jin D, Mutukura T, Charbonneau M, Truong T, Viau S, Johnson LD, Linderoth E, Sievers EL, Maleki Vareki S, Figueredo R, Pampillo M, Koropatnick J, Trudel S, Mbong N, Jin L, Wang JC, and Uger RA. TTI-621 (SIRPalphaFc): A CD47- blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res 23: 1068-1079, 2017.
194. Phelan MW, Forman LW, Perrine SP, and Faller DV. Hypoxia increases thrombospondin-1 transcript and protein in cultured endothelial cells. J Lab Clin Med 132: 519-529, 1998.
195. Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, Dinh T, Zhou M, Strake B, Feng PH, Rocca M, Santos CD, Shan X, Danet-Desnoyers G, Shi F, Kaiser E, Millar HJ, Fenton S, Swanson R, Nemeth JA, and Attar RM. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J 7: E536, 2017.
196. Poczatek MH, Hugo C, Darley-Usmar V, and Murphy- Ullrich JE. Glucose stimulation of transforming growth factor-beta bioactivity in mesangial cells is mediated by thrombospondin-1. Am J Pathol 157: 1353-1363, 2000.
197. Posey KL, Hankenson K, Veerisetty AC, Bornstein P, Lawler J, and Hecht JT. Skeletal abnormalities in mice lacking extracellular matrix proteins, thrombospondin-1, thrombospondin-3, thrombospondin-5, and type IX collagen. Am J Pathol 172: 1664-1674, 2008.
198. Prentice RL, Zhao S, Johnson M, Aragaki A, Hsia J, Jackson RD, Rossouw JE, Manson JE, and Hanash SM. Proteomic risk markers for coronary heart disease and stroke: validation and mediation of randomized trial hormone therapy effects on these diseases. Genome Med 5: 112, 2013.
199. Qin Z, Robichaud P, He T, Fisher GJ, Voorhees JJ, and Quan T. Oxidant exposure induces cysteine-rich protein 61 (CCN1) via c-Jun/AP-1 to reduce collagen expression in human dermal fibroblasts. PLoS One 9: E115402, 2014.
200. Radomski MW, Palmer RM, and Moncada S. An L-Arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 87: 5193-5197, 1990.
201. Rama Rao KV, Curtis KM, Johnstone JT, and Norenberg MD. Amyloid-beta inhibits thrombospondin 1 release fromcultured astrocytes: Effects on synaptic protein expression. J Neuropathol Exp Neurol 72: 735-744, 2013.
202. Raman P, Krukovets I, Marinic TE, Bornstein P, and Stenina OI. Glycosylation mediates up-regulation of a potent antiangiogenic and proatherogenic protein, thrombospondin-1, by glucose in vascular smooth muscle cells. J Biol Chem 282: 5704-5714, 2007.
203. Ramanathan S, Mazzalupo S, Boitano S, and Montfort WR. Thrombospondin-1 and angiotensin II inhibit soluble guanylyl cyclase through an increase in intracellular calcium concentration. Biochemistry 50: 7787-7799, 2011.
204. Repka T and Hebbel RP. Hydroxyl radical formation by sickle erythrocyte membranes: Role of pathologic iron deposits and cytoplasmic reducing agents. Blood 78: 2753-2758, 1991.
205. Ridnour LA, Cheng RY, Weiss JM, Kaur S, Soto-Pantoja DR, Basudhar D, Heinecke JL, Stewart CA, DeGraff W, Sowers AL, Thetford A, Kesarwala AH, Roberts DD, Young HA, Mitchell JB, Trinchieri G, Wiltrout RH, and Wink DA. NOS inhibition modulates immune polarization and improves radiation-induced tumor growth delay. Cancer Res 2015 (in press).
206. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, and Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci U S A 102: 13147-13152, 2005.
207. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, and Wink DA. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci U S A 104: 16898-16903, 2007.
208. Riessen R, Kearney M, Lawler J, and Isner JM. Immunolocalization of thrombospondin-1 in human atherosclerotic and restenotic arteries. Am Heart J 135: 357-364, 1998.
209. Roberts DD. Thrombospondins and their receptors: Evolving functions. In: Evolution of Extracellular Matrix, Biology of Extracellular Matrix, edited by Keeley F, Mecham RP. Berlin Heidelberg: Springer-Verlag, 2013, pp. 221-242.
210. Roberts DD and Lau LF. Matricellular proteins. In: The Extracellular Matrix: An Overview, Biology of Extracellular Matrix, edited by Mecham RP. Berlin Heidelberg: Springer-Verlag, 2011, pp. 369-413.
211. Roberts DD, Miller TW, Rogers NM, Yao M, and Isenberg JS. The matricellular protein thrombospondin-1 globally regulates cardiovascular function and responses to stress. Matrix Biol 31: 162-169, 2012.
212. Rock MJ, Holden P, Horton WA, and Cohn DH. Cartilage oligomeric matrix protein promotes cell attachment via two independent mechanisms involving CD47 and alphaVbeta3 integrin. Mol Cell Biochem 338: 215-224, 2010.
213. Rogers NM, Ghimire K, Calzada MJ, and Isenberg JS. Matricellular protein thrombospondin-1 in pulmonary hypertension: multiple pathways to disease. Cardiovasc Res 2017 (in press).
214. Rogers NM, Roberts DD, and Isenberg JS. Age-Associated induction of cell membrane CD47 limits basal and temperature-induced changes in cutaneous blood flow. Ann Surg 258: 184-191, 2013.
215. Rogers NM, Sharifi-Sanjani M, Yao M, Ghimire K, Bienes-Martinez R, Mutchler SM, Knupp HE, Baust J, Novelli EM, Ross M, St Croix C, Kutten JC, Czajka CA, Sembrat JC, Rojas M, Labrousse-Arias D, Bachman TN, Vanderpool RR, Zuckerbraun BS, Champion HC, Mora AL, Straub AC, Bilonick RA, Calzada MJ, and Isenberg JS. TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction. Cardiovasc Res 113: 15-29, 2017.
216. Rogers NM, Thomson AW, and Isenberg JS. Activation of parenchymal CD47 promotes renal ischemia-reperfusion injury. J Am Soc Nephrol 23: 1538-1550, 2012.
217. Rogers NM, Yao M, Sembrat J, George MP, Knupp H, Ross M, Sharifi-Sanjani M, Milosevic J, St Croix C, Rajkumar R, Frid MG, Hunter KS, Mazzaro L, Novelli EM, Stenmark KR, Gladwin MT, Ahmad F, Champion HC, and Isenberg JS. Cellular, pharmacological, and biophysical evaluation of explanted lungs from a patient with sickle cell disease and severe pulmonary arterial hypertension. Pulm Circ 3: 936-951, 2013.
218. Rogers NM, Zhang ZJ, Wang JJ, Thomson AW, and Isenberg JS. CD47 regulates renal tubular epithelial cell self-renewal and proliferation following renal ischemia reperfusion. Kidney Int 90: 334-347, 2016.
219. Rollo EE, Laskin DL, and Denhardt DT. Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW264.7 macrophages. J Leukoc Biol 60: 397-404, 1996.
220. Roudier E, Milkiewicz M, Birot O, Slopack D, Montelius A, Gustafsson T, Paik JH, DePinho RA, Casale GP, Pipinos, II, and Haas TL. Endothelial FoxO1 is an intrinsic regulator of thrombospondin 1 expression that restrains angiogenesis in ischemic muscle. Angiogenesis 16: 759- 772, 2013.
221. Ruetten H, Dimmeler S, Gehring D, Ihling C, and Zeiher AM. Concentric left ventricular remodeling in endothelial nitric oxide synthase knockout mice by chronic pressure overload. Cardiovasc Res 66: 444-453, 2005.
222. Ruiz-Hurtado G and Delgado C. Nitric oxide pathway in hypertrophied heart: new therapeutic uses of nitric oxide donors. J Hypertens 28 Suppl 1: S56-S61, 2010.
223. Saha S, Chakraborty PK, Xiong X, Dwivedi SK, Mustafi SB, Leigh NR, Ramchandran R, Mukherjee P, and Bhattacharya R. Cystathionine beta-synthase regulates endothelial function via protein S-sulfhydration. FASEB J 30: 441-456, 2016.
224. Sakai LY, Keene DR, Renard M, and De Backer J. FBN1: The disease-causing gene for Marfan syndrome and other genetic disorders. Gene 591: 279-291, 2016.
225. Schuepp BJ and Jungi TW. Thrombospondin-exposed human monocytes display augmented luminol-enhanced chemiluminescence upon receptor triggering. Biochem Biophys Res Commun 177: 1087-1094, 1991.
226. Schuepp BJ, Pfister H, Clemetson KJ, Silverstein RL, and Jungi TW. CD36-mediated signal transduction in human monocytes by anti-CD36 antibodies but not by antithrombospondin antibodies recognizing cell membranebound thrombospondin. Biochem Biophys Res Commun 175: 263-270, 1991.
227. Scott JA, Weir ML, Wilson SM, Xuan JW, Chambers AF, and McCormack DG. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol 275: H2258-H2265, 1998.
228. Seymour K, Han X, Sadowitz B, Maier KG, and Gahtan V. Differential effect of nitric oxide on thrombospondin- 1-, PDGF-And fibronectin-induced migration of vascular smooth muscle cells. Am J Surg 200: 615-619, 2010.
229. Sezaki S, Hirohata S, Iwabu A, Nakamura K, Toeda K, Miyoshi T, Yamawaki H, Demircan K, Kusachi S, Shiratori Y, and Ninomiya Y. Thrombospondin-1 is induced in rat myocardial infarction and its induction is accelerated by ischemia/reperfusion. Exp Biol Med (Maywood) 230: 621-630, 2005.
230. Sharifi-Sanjani M, Shoushtari AH, Quiroz M, Baust J, Sestito SF, Mosher M, Ross M, McTiernan CF, St Croix CM, Bilonick RA, Champion HC, and Isenberg JS. Cardiac CD47 drives left ventricular heart failure through Ca2+-CaMKII-regulated induction of HDAC3. J Am Heart Assoc 3: E000670, 2014.
231. Sharma R and Kale RK. Effect of radiation on glyoxalase I and glyoxalase II activities in spleen and liver of mice. Int J Radiat Biol 63: 233-238, 1993.
232. Shen C, Yan J, Erkocak OF, Zheng XF, and Chen XD. Nitric oxide inhibits autophagy via suppression of JNK in meniscal cells. Rheumatology (Oxford) 53: 1022-1033, 2014.
233. Shen L, Liao L, Chen C, Guo Y, Song D, Wang Y, Chen Y, Zhang K, Ying M, Li S, Liu Q, and Ni J. Proteomics analysis of blood serums from Alzheimer's disease patients using iTRAQ labeling technology. J Alzheimers Dis 56: 361-378, 2017.
234. Shen X, Kolluru GK, Yuan S, and Kevil CG. Measurement of H2S in vivo and in vitro by the monobromobimane method. Methods Enzymol 554: 31-45, 2015.
235. Shen X, Pattillo CB, Pardue S, Bir SC, Wang R, and Kevil CG. Measurement of plasma hydrogen sulfide in vivo and in vitro. Free Radic Biol Med 50: 1021-1031, 2011.
236. Sheshadri P, Ashwini A, Jahnavi S, Bhonde R, Prasanna J, and Kumar A. Novel role of mitochondrial manganese superoxide dismutase in STAT3 dependent pluripotency of mouse embryonic stem cells. Sci Rep 5: 9516, 2015.
237. Shevde LA and Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol 37: 131-141, 2014.
238. Shih B, Sultan MJ, Chaudhry IH, Tan KT, Johal KS, Marstan A, Tsai M, Baguneid M, and Bayat A. Identification of biomarkers in sequential biopsies of patients with chronic wounds receiving simultaneous acute wounds: A genetic, histological, and noninvasive imaging study. Wound Repair Regen 20: 757-769, 2012.
239. Shimazaki M, Nakamura K, Kii I, Kashima T, Amizuka N, Li M, Saito M, Fukuda K, Nishiyama T, Kitajima S, Saga Y, Fukayama M, Sata M, and Kudo A. Periostin is essential for cardiac healing after acute myocardial infarction. J Exp Med 205: 295-303, 2008.
240. Sikic BI, Narayanan S, Colevas AD, Padda SK, Fisher GA, Supan D, Wakelee HA, Aoki R, Pegram MD, Villalobos VM, Liu J, Chao M, Volkmer J-P, Majeti R, and Weissman IL. A first-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 34: Abstr 3019, 2016.
241. Simmers P, Gishto A, Vyavahare N, and Kothapalli CR. Nitric oxide stimulates matrix synthesis and deposition by adult human aortic smooth muscle cells within threedimensional cocultures. Tissue Eng Part A 21: 1455- 1470, 2015.
242. Smadja DM, d'Audigier C, Bieche I, Evrard S, Mauge L, Dias JV, Labreuche J, Laurendeau I, Marsac B, Dizier B, Wagner-Ballon O, Boisson-Vidal C, Morandi V, Duong- Van-Huyen JP, Bruneval P, Dignat-George F, Emmerich J, and Gaussem P. Thrombospondin-1 is a plasmatic marker of peripheral arterial disease that modulates endothelial progenitor cell angiogenic properties. Arterioscler Thromb Vasc Biol 31: 551-559, 2011.
243. Sockolosky JT, Dougan M, Ingram JR, Ho CC, Kauke MJ, Almo SC, Ploegh HL, and Garcia KC. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A 113: E2646-E2654, 2016.
244. Soto-Pantoja DR, Kaur S, and Roberts DD. CD47 signaling pathways controlling cellular differentiation and responses to stress. Crit Rev Biochem Mol Biol 50: 212- 230, 2015.
245. Soto-Pantoja DR, Miller TW, Pendrak ML, Degraff WG, Sullivan C, Ridnour LA, Abu-Asab M, Wink DA, Tsokos M, and Roberts DD. CD47 deficiency confers cell and tissue radioprotection by activation of autophagy. Autophagy 8: 1628-1642, 2012.
246. Soto-Pantoja DR, Ridnour LA, Wink DA, and Roberts DD. Blockade of CD47 increases survival of mice exposed to lethal total body irradiation. Sci Rep 3: 1038, 2013.
247. Soto-Pantoja DR, Sipes JM, Ghosh A, Merino MJ, and Roberts DD. Therapeutic targeting of CD47 regulates cell bioenergetics and autophagy to reduce breast tumor growth and protect against anthracycline-mediated cardiac toxicity. Cancer Res 74: Abstract nr 2434, 2014.
248. Soto-Pantoja DR, Sipes JM, Martin-Manso G, Westwood B, Morris NL, Ghosh A, Emenaker NJ, and Roberts DD. Dietary fat overcomes the protective activity of thrombospondin-1 signaling in the Apc(Min/+) model of colon cancer. Oncogenesis 5: E230, 2016.
249. Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, De- Graff WG, Wink DA, Berzofsky JA, and Roberts DD. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74: 6771-6783, 2014.
250. Spassov S, Pfeifer D, Strosing K, Ryter S, Hummel M, Faller S, and Hoetzel A. Genetic targets of hydrogen sulfide in ventilator-induced lung injury-A microarray study. PLoS One 9: E102401, 2014.
251. Spenle C, Saupe F, Midwood K, Burckel H, Noel G, and Orend G. Tenascin-C: Exploitation and collateral damage in cancer management. Cell Adh Migr 9: 141-153, 2015.
252. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, and Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408, 2006.
253. Staines KA, MacRae VE, and Farquharson C. The importance of the SIBLING family of proteins on skeletal mineralisation and bone remodelling. J Endocrinol 214: 241-255, 2012.
254. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, and Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 30: 1078-1094, 2011.
255. Stein EV, Miller TW, Ivins-O'Keefe K, Kaur S, and Roberts DD. Secreted thrombospondin-1 regulates macrophage interleukin-1beta production and activation through CD47. Sci Rep 6: 19684, 2016.
256. Stevens AL, Wheeler CA, Tannenbaum SR, and Grodzinsky AJ. Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-Alpha but not IL-1beta treatment at a post-Transcriptional level in bovine cartilage explants. Osteoarthritis Cartilage 16: 489-497, 2008.
257. Suchard SJ and Boxer LA. Exocytosis of a subpopulation of specific granules coincides with H2O2 production in adherent human neutrophils. J Immunol 152: 290-300, 1994.
258. Suchard SJ, Boxer LA, and Dixit VM. Activation of human neutrophils increases thrombospondin receptor expression. J Immunol 147: 651-659, 1991.
259. Suchard SJ, Burton MJ, Dixit VM, and Boxer LA. Human neutrophil adherence to thrombospondin occurs through a CD11/CD18-independent mechanism. J Immunol 146: 3945-3952, 1991.
260. Sun X, Skorstengaard K, and Mosher DF. Disulfides modulate RGD-inhibitable cell adhesive activity of thrombospondin. J Cell Biol 118: 693-701, 1992.
261. Suzuma K, Takagi H, Otani A, Oh H, and Honda Y. Expression of thrombospondin-1 in ischemia-induced retinal neovascularization. Am J Pathol 154: 343-354, 1999.
262. Szabo C. Gasotransmitters in cancer: from pathophysiology to experimental therapy. Nat Rev Drug Discov 15: 185-203, 2016.
263. Szabo C. Hydrogen sulfide, an enhancer of vascular nitric oxide signaling: mechanisms and implications. Am J Physiol Cell Physiol 312: C3-C15, 2017.
264. Takayama H, Hamner CE, Caccitolo JA, Hisamochi K, Pearson PJ, and Schaff HV. A novel antioxidant, EPC-K1, stimulates endothelial nitric oxide production and scavenges hydroxyl radicals. Circ J 67: 1046-1052, 2003.
265. Talaei F, Bouma HR, Hylkema MN, Strijkstra AM, Boerema AS, Schmidt M, and Henning RH. The role of endogenous H2S formation in reversible remodeling of lung tissue during hibernation in the Syrian hamster. J Exp Biol 215: 2912-2919, 2012.
266. Talaei F, Hylkema MN, Bouma HR, Boerema AS, Strijkstra AM, Henning RH, and Schmidt M. Reversible remodeling of lung tissue during hibernation in the Syrian hamster. J Exp Biol 214: 1276-1282, 2011.
267. Tang Y, Scheef EA, Gurel Z, Sorenson CM, Jefcoate CR, and Sheibani N. CYP1B1 and endothelial nitric oxide synthase combine to sustain proangiogenic functions of endothelial cells under hyperoxic stress. Am J Physiol Cell Physiol 298: C665-C678, 2010.
268. Tao BB, Liu SY, Zhang CC, Fu W, Cai WJ, Wang Y, Shen Q, Wang MJ, Chen Y, Zhang LJ, Zhu YZ, and Zhu YC. VEGFR2 functions as an H2S-Targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells. Antioxid Redox Signal 19: 448-464, 2013.
269. Tao H, Qian P, Wang F, Yu H, and Guo Y. Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in esophageal squamous cell cancer preclinical model. Oncol Res 2017 [Epub ahead of print]; DOI:10.3727/096504017X14900505020895.
270. Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, and Rephaeli A. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs 30: 130-143, 2012.
271. Tejedo JR, Tapia-Limonchi R, Mora-Castilla S, Cahuana GM, Hmadcha A, Martin F, Bedoya FJ, and Soria B. Low concentrations of nitric oxide delay the differentiation of embryonic stem cells and promote their survival. Cell Death Dis 1: E80, 2010.
272. Thakar CV, Zahedi K, Revelo MP, Wang Z, Burnham CE, Barone S, Bevans S, Lentsch AB, Rabb H, and Soleimani M. Identification of thrombospondin 1 (TSP-1) as a novel mediator of cell injury in kidney ischemia. J Clin Invest 115: 3451-3459, 2005.
273. Thomas DD, Heinecke JL, Ridnour LA, Cheng RY, Kesarwala AH, Switzer CH, McVicar DW, Roberts DD, Glynn S, Fukuto JM, Wink DA, and Miranda KM. Signaling and stress: The redox landscape in NOS2 biology. Free Radic Biol Med 87: 204-225, 2015.
274. Thornalley PJ. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-A role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 27: 565- 573, 1996.
275. Toda N and Ayajiki K. Phylogenesis of constitutively formed nitric oxide in non-mammals. Rev Physiol Biochem Pharmacol 157: 31-80, 2006.
276. Tong X, Khandelwal AR, Qin Z, Wu X, Chen L, Ago T, Sadoshima J, and Cohen RA. Role of smooth muscle Nox4-based NADPH oxidase in neointimal hyperplasia. J Mol Cell Cardiol 89: 185-194, 2015.
277. Topol EJ, McCarthy J, Gabriel S, Moliterno DJ, Rogers WJ, Newby LK, Freedman M, Metivier J, Cannata R, O'Donnell CJ, Kottke-Marchant K, Murugesan G, Plow EF, Stenina O, and Daley GQ. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 104: 2641-2644, 2001.
278. Trezzini C, Jungi TW, Spycher MO, Maly FE, and Rao P. Human monocytes CD36 and CD16 are signaling molecules. Evidence from studies using antibody-induced chemiluminescence as a tool to probe signal transduction. Immunology 71: 29-37, 1990.
279. Tsoutsman T, Wang X, Garchow K, Riser B, Twigg S, and Semsarian C. CCN2 plays a key role in extracellular matrix gene expression in severe hypertrophic cardiomyopathy and heart failure. J Mol Cell Cardiol 62: 164-178, 2013.
280. Tulasne D, Judd BA, Johansen M, Asazuma N, Best D, Brown EJ, Kahn M, Koretzky GA, and Watson SP. Cterminal peptide of thrombospondin-1 induces platelet aggregation through the Fc receptor gamma-chainassociated signaling pathway and by agglutination. Blood 98: 3346-3352, 2001.
281. Tuszynski GP, Rothman VL, Murphy A, Siegler K, and Knudsen KA. Thrombospondin promotes platelet aggregation. Blood 72: 109-115, 1988.
282. Urao N, Inomata H, Razvi M, Kim HW, Wary K, McKinney R, Fukai T, and Ushio-Fukai M. Role of nox2- based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res 103: 212-220, 2008.
283. Ushio-Fukai M. Compartmentalization of redox signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal 11: 1289-1299, 2009.
284. Valitutti S, Castellino F, and Musiani P. Effect of sulfurous (thermal) water on T lymphocyte proliferative response. Ann Allergy 65: 463-468, 1990.
285. van Almen GC, Swinnen M, Carai P, Verhesen W, Cleutjens JP, D'Hooge J, Verheyen FK, Pinto YM, Schroen B, Carmeliet P, and Heymans S. Absence of thrombospondin-2 increases cardiomyocyte damage and matrix disruption in doxorubicin-induced cardiomyopathy. J Mol Cell Cardiol 51: 318-328, 2011.
286. von Toerne C, Huth C, de Las Heras Gala T, Kronenberg F, Herder C, Koenig W, Meisinger C, Rathmann W, Waldenberger M, Roden M, Peters A, Thorand B, and Hauck SM. MASP1, THBS1, GPLD1 and ApoA-IV are novel biomarkers associated with prediabetes: The KORA F4 study. Diabetologia 59: 1882-1892, 2016.
287. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, and Mason RM. Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48: 2650-2660, 2005.
288. Walpen S, Beck KF, Eberhardt W, Apel M, Chatterjee PK, Wray GM, Thiemermann C, and Pfeilschifter J. Downregulation of SPARC expression is mediated by nitric oxide in rat mesangial cells and during endotoxemia in the rat. J Am Soc Nephrol 11: 468-476, 2000.
289. Wang HB, Yang J, Ding JW, Chen LH, Li S, Liu XW, Yang CJ, Fan ZX, and Yang J. RNAi-mediated downregulation of CD47 protects against ischemia/reperfusioninduced myocardial damage via activation of eNOS in a rat model. Cell Physiol Biochem 40: 1163-1174, 2016.
290. Wang MJ, Cai WJ, Li N, Ding YJ, Chen Y, and Zhu YC. The hydrogen sulfide donor NaHS promotes angiogenesis in a rat model of hind limb ischemia. Antioxid Redox Signal 12: 1065-1077, 2010.
291. Wang R. Physiological implications of hydrogen sulfide: A whiff exploration that blossomed. Physiol Rev 92: 791- 896, 2012.
292. Wang S, Shiva S, Poczatek MH, Darley-Usmar V, and Murphy-Ullrich JE. Nitric oxide and cGMP-dependent protein kinase regulation of glucose-mediated thrombospondin 1-dependent transforming growth factor-beta activation in mesangial cells. J Biol Chem 277: 9880-9888, 2002.
293. Wang S, Skorczewski J, Feng X, Mei L, and Murphy- Ullrich JE. Glucose up-regulates thrombospondin 1 gene transcription and transforming growth factor-beta activity through antagonism of cGMP-dependent protein kinase repression via upstream stimulatory factor 2. J Biol Chem 279: 34311-34322, 2004.
294. Wang S, Wu X, Lincoln TM, and Murphy-Ullrich JE. Expression of constitutively active cGMP-dependent protein kinase prevents glucose stimulation of thrombospondin 1 expression and TGF-beta activity. Diabetes 52: 2144-2150, 2003.
295. Wang Y, Wang X, Liang X, Wu J, Dong S, Li H, Jin M, Sun D, Zhang W, and Zhong X. Inhibition of hydrogen sulfide on the proliferation of vascular smooth muscle cells involved in the modulation of calcium sensing receptor in high homocysteine. Exp Cell Res 347: 184-191, 2016.
296. Wani J, Carl M, Henger A, Nelson PJ, and Rupprecht H. Nitric oxide modulates expression of extracellular matrix genes linked to fibrosis in kidney mesangial cells. Biol Chem 388: 497-506, 2007.
297. Wardman P, Rothkamm K, Folkes LK, Woodcock M, and Johnston PJ. Radiosensitization by nitric oxide at low radiation doses. Radiat Res 167: 475-484, 2007.
298. Wessel J, Topol EJ, Ji M, Meyer J, and McCarthy JJ. Replication of the association between the thrombospondin-4 A387P polymorphism and myocardial infarction. Am Heart J 147: 905-909, 2004.
299. Whiteman M, Li L, Rose P, Tan CH, Parkinson DB, and Moore PK. The effect of hydrogen sulfide donors on lipopolysaccharide-induced formation of inflammatory mediators in macrophages. Antioxid Redox Signal 12: 1147-1154, 2010.
300. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, and Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci U S A 90: 9813-9817, 1993.
301. Wong JC and Fiscus RR. Essential roles of the nitric oxide (no)/cGMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway and the atrial natriuretic peptide (ANP)/cGMP/PKG-Ialpha autocrine loop in promoting proliferation and cell survival of OP9 bone marrow stromal cells. J Cell Biochem 112: 829-839, 2011.
302. Wu H, Chen L, Xie J, Li R, Li GN, Chen QH, Zhang XL, Kang LN, and Xu B. Periostin expression induced by oxidative stress contributes to myocardial fibrosis in a rat model of high salt-induced hypertension. Mol Med Rep 14: 776-782, 2016.
303. Wu SY, Pan CS, Geng B, Zhao J, Yu F, Pang YZ, Tang CS, and Qi YF. Hydrogen sulfide ameliorates vascular calcification induced by vitamin D3 plus nicotine in rats. Acta Pharmacol Sin 27: 299-306, 2006.
304. Xiao Z, Banan B, Xu M, Jia J, Manning PT, Hiebsch RR, Gunasekaran M, Upadhya GA, Frazier WA, Mohanakumar T, Lin Y, and Chapman WC. Attenuation of ischemia-reperfusion injury and improvement of survival in recipients of steatotic rat livers using CD47 monoclonal antibody. Transplantation 100: 1480-1489, 2016.
305. Xiao ZY, Banan B, Jia J, Manning PT, Hiebsch RR, Gunasekaran M, Upadhya GA, Frazier WA, Mohanakumar T, Lin Y, and Chapman WC. CD47 blockade reduces ischemia/reperfusion injury and improves survival in a rat liver transplantation model. Liver Transpl 21: 468-477, 2015.
306. Yamamoto K, Dang QN, Kennedy SP, Osathanondh R, Kelly RA, and Lee RT. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J Biol Chem 274: 21840-21846, 1999.
307. Yan Y and Finkel T. Autophagy as a regulator of cardiovascular redox homeostasis. Free Radic Biol Med 109: 108-113, 2016.
308. Yao M, Rogers NM, Csanyi G, Rodriguez AI, Ross MA, St Croix C, Knupp H, Novelli EM, Thomson AW, Pagano PJ, and Isenberg JS. Thrombospondin-1 activation of signal-regulatory protein-Alpha stimulates reactive oxygen species production and promotes renal ischemia reperfusion injury. J Am Soc Nephrol 25: 1171-1186, 2014.
309. 308. Yoshioka J, Chutkow WA, Lee S, Kim JB, Yan J, Tian R, Lindsey ML, Feener EP, Seidman CE, Seidman JG, and Lee RT. Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest 122: 267-279, 2012.
310. Yoshioka J and Lee RT. Thioredoxin-interacting protein and myocardial mitochondrial function in ischemiareperfusion injury. Trends Cardiovasc Med 24: 75-80, 2014.
311. Zhang ZX, Shek K, Wang S, Huang X, Lau A, Yin Z, Sun H, Liu W, Garcia B, Rittling S, and Jevnikar AM. Osteopontin expressed in tubular epithelial cells regulates NK cell-mediated kidney ischemia reperfusion injury. J Immunol 185: 967-973, 2010.
312. Zhao X, Ding EY, Yu OM, Xiang SY, Tan-Sah VP, Yung BS, Hedgpeth J, Neubig RR, Lau LF, Brown JH, and Miyamoto S. Induction of the matricellular protein CCN1 through RhoA and MRTF-A contributes to ischemic cardioprotection. J Mol Cell Cardiol 75: 152- 161, 2014.
313. Zhao X, Zhang LK, Zhang CY, Zeng XJ, Yan H, Jin HF, Tang CS, and Du JB. Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertens Res 31: 1619-1630, 2008.
314. Zhao Y, Wang S, Sorenson CM, Teixeira L, Dubielzig RR, Peters DM, Conway SJ, Jefcoate CR, and Sheibani N. Cyp1b1 mediates periostin regulation of trabecular meshwork development by suppression of oxidative stress. Mol Cell Biol 33: 4225-4240, 2013.
315. Zhao Y, Xiong Z, Lechner EJ, Klenotic PA, Hamburg BJ, Hulver M, Khare A, Oriss T, Mangalmurti N, Chan Y, Zhang Y, Ross MA, Stolz DB, Rosengart MR, Pilewski J, Ray P, Ray A, Silverstein RL, and Lee JS.Thrombospondin-1 triggers macrophage IL-10 production and promotes resolution of experimental lung injury. Mucosal Immunol 7: 440-448, 2014.
316. Zheng Y, Liao F, Lin X, Zheng F, Fan J, Cui Q, Yang J, Geng B, and Cai J. Cystathionine gamma-lyase-hydrogen sulfide induces runt-related transcription factor 2 dulfhydration, thereby increasing osteoblast activity to promote bone fracture healing. Antioxid Redox Signal 2017 [Epub ahead of print]; DOI:10.1089/ars.2016.6826.
317. Zhong ZY and Tang Y. Upregulation of periostin prevents high glucose-induced mitochondrial apoptosis in human umbilical vein endothelial cells via activation of Nrf2/HO- 1 signaling. Cell Physiol Biochem 39: 71-80, 2016.
318. Zwicker JI, Peyvandi F, Palla R, Lombardi R, Canciani MT, Cairo A, Ardissino D, Bernardinelli L, Bauer KA, Lawler J, and Mannucci P. The thrombospondin-1N700S polymorphism is associated with early myocardial infarction without altering von Willebrand factor multimer size. Blood 108: 1280-1283, 2006